Dhanuka Agritech Ltd Q3 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 4 Aug 2026 | Fertilizers & Agrochemicals | Market Cap: ₹4.5K Cr
FY '26 top line growth expected around 15% excluding Bayer molecules; additional revenue from Bayer products will add to this (Page 17). Top-line growth for FY '26 is expected around 15%, excluding revenue from Bayer molecules, which will add incremental growth.
From Dhanuka Agritech Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹980
Market Cap
₹4.5K Cr
P/E Ratio
16.7
How does Dhanuka Agritech Ltd rank in Fertilizers & Agrochemicals?
Compare Dhanuka Agritech Ltd against every Fertilizers & Agrochemicals company this quarter on revenue, margins and earnings-call signals.
Dhanuka Agritech Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹483 Cr, net profit ₹98 Cr.
Full financials →📊 Revenue & Sales Performance
- →FY '26 top line growth expected around 15% excluding Bayer molecules; additional revenue from Bayer products will add to this (Page 17).
- →Volume growth for FY '26 is expected to be largely in line with top line growth, i.e., around 15% (Page 17).
- →Bayer product revenues projected to grow at 15% year-on-year for the first 5 years starting FY '27 (Page 9).
- →Specialty products and new product launches expected to drive volume growth, while generic products show no significant value growth but slight volume increase (Page 12, 16).
- →New registrations and marketing efforts are planned to revive and grow acquired Bayer products by 10-15% CAGR in subsequent years (Page 14).
- →Launch of about 8 new products in the next 2 years targeting crops like rice, grapes, and horticulture is planned (Page 8).
- →Continued focus on domestic market growth with limited growth from exports (Page 17).
📈 Profitability & Margins
- →Top-line growth for FY '26 is expected around 15%, excluding revenue from Bayer molecules, which will add incremental growth.
- →Volume growth for FY '26 is anticipated to be largely in line with overall top-line growth (~15%), indicating volume-driven growth.
- →Revenue contribution from Bayer products will transition gradually in FY '26, with full revenue recognition expected by FY '27; 15% year-on-year growth expected in Bayer product revenues for first 5 years starting FY '27.
- →EBITDA margins for acquired Bayer products expected to align with existing company margins.
- →Interest cost has increased due to INR 50 crore loan for acquisition repayment by December 2025; however, the base cost remains nominal.
- →Margin improvement is expected to be challenging beyond current best levels (38%-39% gross margin), with focus on sustaining margins despite market and pricing challenges.
- →Profitability improvements anticipated as royalty income from Bayer acquisitions begins in FY '26, with clearer details expected by end of February 2025.
🏗️ Capital Expenditure Plans
- →No fresh CAPEX planned for Dahej plant currently due to low commercial viability of new products.
- →Focus on product development in R&D for new products over the next 2-3 years.
- →Intend to launch around 8 new products over the next 2 years, including rice herbicide and fungicide for grapes and horticultural crops in FY '26.
- →One molecule manufacturing shift planned to India, expected to take around 1.5 to 2 years for regulatory approvals; another product manufacturing will remain outsourced.
- →No fresh CAPEX at Dahej justified currently; efforts are on product development without major investments.
- →For international business, building a specialist team and adding positions to increase capabilities.
- →Acquisition of Bayer products involved capitalizing INR 160 crores in Q4; no additional CAPEX mentioned specifically for this acquisition.
💰 Fundraising & Capital Structure
- →The company raised short-term borrowings of INR 50 crores in December for an acquisition.
- →This loan is expected to be repaid before December 2025.
- →Apart from this, the company has utilized some limits temporarily around the time of a buyback in September.
- →No mention of any new or future fundraising through equity was made.
- →Any additional clarity on royalties and financial impacts related to acquisitions is expected by end of February.
- →Overall, no explicit announcement of current/future large debt or equity fundraising beyond these short-term arrangements.
📋 Order Book & Pipeline
- →The transcript does not explicitly mention the current or expected order book or pending orders for Dhanuka Agritech Limited.
- →However, it is indicated that the company expects to generate revenue from Bayer-acquired products, with full transition to Dhanuka's books by FY '27.
- →For FY '26, revenue from these products is expected in the range of INR 60-70 crores.
- →The company plans around 8 new product launches over the next 2 years to support growth.
- →Domestic formulation business is growing, driven largely by specialty products, with volume growth expected around 15% excluding Bayer molecules.
- →Channel inventory for Dhanuka is minimal, suggesting efficient inventory management and steady order flow.
- →No explicit mention of backlog or pending orders was made in the call.
Key Metrics
Frequently Asked Questions
What were Dhanuka Agritech Ltd Q3 FY25 results?
FY '26 top line growth expected around 15% excluding Bayer molecules; additional revenue from Bayer products will add to this (Page 17). Top-line growth for FY '26 is expected around 15%, excluding revenue from Bayer molecules, which will add incremental growth.
What is Dhanuka Agritech Ltd share price analysis?
Dhanuka Agritech Ltd currently shows a neutral. The stock trades at a P/E of 16.7 with a market cap of ₹4,482 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dhanuka Agritech Ltd planning capital expenditure?
No fresh CAPEX planned for Dahej plant currently due to low commercial viability of new products.
Keep Dhanuka Agritech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.